Neogen (NEOG) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed QuidelOrtho (QDEL) over the past year, gaining 101.2% versus a loss of 55.5%. Over five years, NEOG leads with a -71.5% price change compared with -90.3% for QDEL. Neogen is the larger company by market cap ($2.59 billion vs $920.3 million), about 2.8 times the size.
On valuation, QuidelOrtho trades at a lower forward P/E (9.3x vs 31.2x for Neogen).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEOG | QDEL |
|---|---|---|
| Share price | $11.85 | $13.42 |
| Market cap | $2.59B | $920.28M |
| 1-day change | +1.20% | +8.14% |
| YTD return | +67.53% | -56.55% |
| 1-year return | +101.20% | -55.46% |
| 5-year return | -71.47% | -90.32% |
| Forward P/E | 31.18 | 9.31 |
| EPS (TTM) | $-0.26 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $870.40M | — |
| Revenue growth (YoY) | -2.72% | — |
| Net income (latest FY) | $-7.90M | — |
| Gross margin | 46.93% | — |
| Operating margin | -2.48% | — |
| Net margin | -0.91% | — |
| 52-week high | $14.26 | $35.58 |
| 52-week low | $5.37 | $9.92 |
| Distance from 52-week high | -16.90% | -62.28% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +18.14% | +9.31% |
| Average volume | 3.14M | 1.51M |
| Shares outstanding | 218.31M | 68.58M |
| Employees | 2,636 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neogen is about 2.8 times larger than QuidelOrtho by market value ($2.59B vs $920.28M).
- NEOG has outperformed QDEL by 156.7 percentage points over the past year.
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
NEOG vs QDEL FAQ
Which is bigger, Neogen or QuidelOrtho?
Neogen (NEOG) is larger, with a market capitalization of $2.59B compared with $920.28M for QuidelOrtho (QDEL).
Which stock has performed better over the past year, NEOG or QDEL?
NEOG returned +101.20% over the past 12 months, compared with -55.46% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Neogen and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.